Pneumonia

Category

Icahn School of Medicine at Mount Sinai Drives Collaborative Investigation into use of Nintedanib in COVID-19 Patients with Fibrosing ILD

New York City’s preeminent Icahn School of Medicine at Mount Sinai, Department of Medicine’s Clinical Trials Office (CTO) and collaborative partner Boehringer Ingelheim, the world’s largest privately held pharmaceutical company based in Germany, announced that the...

Remdesivir Use in Multi-National Clinical Trial of Patients with Moderate COVID-19 & Pneumonia: Perplexing Results

Remdesivir is the only therapy in the United States approved, under emergency use status, as a treatment for COVID-19 along with the just announced convalescent plasma. Referred to as not a ‘knockout drug’ by Dr. Anthony Fauci, Director of the National Institutes of...

Ansun Biopharma’s DAS181 Shows Promise in COVID-19 Patients with Respiratory Challenges

Recently, the Wall Street Journal introduced a small, 25-person San Diego-based biotech called Ansun Biophrma (Ansun) reporting on recent success of a drug that cleared COVID-19 symptoms in a small study involving four Chinese patients. With a strong background in...

Virginia Commonwealth Commences Canakinumab Study Targeting Severe COVID-19 Patients with Pneumonia

Virginia Commonwealth University (VCU), a prominent public research university in Richmond, Virginia, became one of the first clinical investigational sites in the world to begin clinical trials to study the safety and efficacy of the Novartis drug canakinumab on...

Aridis Pharmaceuticals Enrolls First COVID-19 Patient in Phase III Study for Patients on Mechanical Ventilators with ‘Superinfection’

Aridis Pharmaceuticals, Inc (NASDAQ: ARDS) announced the enrollment of its first COVID-19 patient in an ongoing Phase III clinical trial of its investigational AR-301, a monoclonal antibody against S. aureus induced pneumonia in patients who were already on mechanical...

Acceleration of First-Patient-First-Visit Study Milestone as Roche Study Investigating Tocilizumab in COVID-19 Pneumonia Patients Enrolls Patients in Spain

Roche recently announce the launch of a global study in collaboration with the U.S. Biomedical Advanced Research and Development Authority (BARDA) to evaluate the safety and efficacy of Actemra/RoActemra (tocilizumab) plus standard of care in hospitalized adult...

Genentech (Roche) Collaborates with BARDA to Launch Actemra Clinical Trial for Adult Patients with Severe COVID-19 Pneumonia

Genentech (Roche) plans a Phase III clinical trial to assess its marketed drug Actemra (tocilizumab) as a treatment for severe cases of COVID-19 in adults. In collaboration with the Biomedical Advanced Research and Development Authority (BARDA), the prominent company...